←back to thread

Goldman Sachs asks in biotech Report: Is curing patients a sustainable business? (2018)

(www.cnbc.com)
249 points randycupertino | 1 comments | 16 Nov 25 23:01 UTC | HN request time: 0s | source
Show context
snowwrestler ◴[16 Nov 25 23:39 UTC] No.45949515[source]▶
It doesn’t matter if it is a sustainable business. People will do what they can to maximize their income now. If 10 companies are withholding a cure to milk the patients, any one of them can break from that strategy at any time, with near-instant financial reward and competitive advantage. It is not a stable equilibrium.
replies(3): >>45949532 #>>45949904 #>>45953315 #
idontwantthis ◴[16 Nov 25 23:41 UTC] No.45949532[source]▶
As long as government regulation prevents them from forming a cartel.
replies(3): >>45949579 #>>45950574 #>>45955111 #
AuthAuth ◴[16 Nov 25 23:48 UTC] No.45949579[source]▶
It shouldnt be limited to companies within the country. Any foreign company can be a market disruptor here. Assuming the drug approval admin isnt working alongside the 'cartel'.
replies(2): >>45949918 #>>45950845 #
1. ComplexSystems ◴[17 Nov 25 04:27 UTC] No.45950845[source]▶
And only in the very particular scenario of a national-only cartel which has not successfully roped in other international pharma companies.